HSBC Holdings plc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? HSBC Holdings plc trades at $92.84 (market cap $311.92B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.64 (market cap $6.04B). The key difference: HSBC Holdings plc is far larger — about 51.6× Iovance Biotherapeutics Inc. Common Stock's market cap, and HSBC Holdings plc pays a 4.05% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| HSBC | IOVA | |
|---|---|---|
Market Cap | $311.92B | $6.04B |
Volume | 3,546,658 | 14,805,993 |
Sector | Financials | Health |
52-Week High | $107.86 | $14.82 |
52-Week Low | $65.67 | $1.81 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $222.19B | $5.97B |
Dividend Yield | 4.05% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.80, down 0.97% with bearish technical signals. The stock shows strong profitability with 34.54% net margin and reasonable valuation at 13.23 P/E. Recent earnings were mixed with Q2 beat but Q1 miss. Analyst sentiment is cautious with 38% buy ratings. The bank is expanding in technology banking and US wealth services while restructuring European operations.
HSBC offers value with solid fundamentals but faces near-term headwinds from technical weakness and mixed earnings performance. Growth opportunities in Asian markets and wealth management balance risks from European restructuring and CFO transition in 2027.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →